{"generic":"Conjugated Estrogens\/Medroxyprogesterone Acetate","drugs":["Conjugated Estrogens\/Medroxyprogesterone Acetate","Premphase","Prempro","Prempro Low Dose"],"mono":{"0":{"id":"923256-s-0","title":"Generic Names","mono":"Conjugated Estrogens\/Medroxyprogesterone Acetate"},"1":{"id":"923256-s-1","title":"Dosing and Indications","sub":{"0":{"id":"923256-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Menopause - Moderate to severe abnormal vasomotor function:<\/b> PREMPRO(R), 1 tablet ORALLY once daily; limit to the lowest possible dose for the shortest duration and reevaluate periodically to determine if treatment is still necessary<\/li><li><b>Menopause - Moderate to severe abnormal vasomotor function:<\/b> PREMPHASE(R), one tablet containing conjugated estrogens 0.625 mg ORALLY on days 1 through 14 followed by 1 tablet containing conjugated estrogens 0.625 mg\/medroxyPROGESTERone acetate 5 mg ORALLY on days 15 through 28; limit to the lowest possible dose for the shortest duration and reevaluate periodically to determine if treatment is still necessary<\/li><li><b>Menopause - Moderate to severe vaginal atrophy - Moderate to severe vulvar atrophy:<\/b> PREMPRO(R), 1 tablet ORALLY once daily; limit to the lowest possible dose for the shortest duration and reevaluate periodically to determine if treatment is still necessary<\/li><li><b>Menopause - Moderate to severe vaginal atrophy - Moderate to severe vulvar atrophy:<\/b> PREMPHASE(R), one tablet containing conjugated estrogens 0.625 mg ORALLY on days 1 through 14 followed by 1 tablet containing conjugated estrogens 0.625 mg\/medroxyPROGESTERone acetate 5 mg ORALLY on days 15 through 28; limit to the lowest possible dose for the shortest duration and reevaluate periodically to determine if treatment is still necessary<\/li><li><b>Postmenopausal osteoporosis, In women with an intact uterus; Prophylaxis:<\/b> PREMPRO(R), 1 tablet ORALLY once daily; limit to the lowest possible dose for the shortest duration and reevaluate periodically to determine if treatment is still necessary<\/li><li><b>Postmenopausal osteoporosis, In women with an intact uterus; Prophylaxis:<\/b> PREMPHASE(R), one tablet containing conjugated estrogens 0.625 mg ORALLY on days 1 through 14 followed by 1 tablet containing conjugated estrogens 0.625 mg\/medroxyPROGESTERone acetate 5 mg ORALLY on days 15 through 28; limit to the lowest possible dose for the shortest duration and reevaluate periodically to determine if treatment is still necessary<\/li><\/ul>"},"1":{"id":"923256-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in children "},"3":{"id":"923256-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Menopause - Moderate to severe abnormal vasomotor function<\/li><li>Menopause - Moderate to severe vaginal atrophy - Moderate to severe vulvar atrophy<\/li><li>Postmenopausal osteoporosis, In women with an intact uterus; Prophylaxis<\/li><\/ul>"}}},"2":{"id":"923256-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of stroke and deep vein thrombosis in postmenopausal women (50 to 79 years of age) using estrogen alone have been reported. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) using estrogens combined with progestins have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported in women receiving estrogen alone or estrogen combined with progestins. Unopposed estrogens increase the risk of endometrial cancer. Adding a progestin will reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Diagnostic measures should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible..<br\/>"},"3":{"id":"923256-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923256-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylactic reaction or angioedema to conjugated estrogens\/medroxyPROGESTERone acetate, known<\/li><li>arterial thromboembolic disease, active, recent, or history (eg, stroke, myocardial infarction)<\/li><li>breast cancer, known, suspected, or history<\/li><li>deep vein thrombosis or pulmonary embolism, active or history<\/li><li>estrogen-dependent neoplasia, known or suspected<\/li><li>genital bleeding, undiagnosed abnormal<\/li><li>liver dysfunction or disease, known<\/li><li>pregnancy, known or suspected<\/li><li>protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders<\/li><\/ul>"},{"id":"923256-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular disorders, estrogens with or without progestins should not be used for the prevention of cardiovascular disease<\/li><li>dementia, increased risk with estrogen-alone and with conjugated estrogen plus progestin therapy in postmenopausal women aged 65 years and older; do not use for the prevention of dementia<\/li><li>breast cancer, invasive; increased risk; monitoring recommended<\/li><li>cardiovascular events (DVT, pulmonary embolism, stroke, and myocardial infarction); increased risk in postmenopausal women aged 50 to 79 years; discontinue immediately if suspected<\/li><li>arterial vascular disease risk factors (eg, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, obesity); manage appropriately<\/li><li>asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas; estrogen therapy may exacerbate these conditions<\/li><li>breast cancer and bone metastasis; severe hypercalcemia may occur; discontinue and institute appropriate measures<\/li><li>cholestatic jaundice associated with past estrogen use or with pregnancy, may decrease estrogen metabolism; discontinue with recurrence<\/li><li>elderly women; increased relative risk of nonfatal stroke, invasive breast cancer, and dementia<\/li><li>endometrial cancer; increased risk with unopposed estrogen in women with intact uteri<\/li><li>fluid retention may occur; monitor patients with conditions that may be exacerbated (cardiac or renal dysfunction)<\/li><li>gallbladder disease requiring surgery, estrogen increases risk 2- to 4-fold in postmenopausal women<\/li><li>hereditary angioedema may be exacerbated by estrogen therapy<\/li><li>hypertriglyceridemia, may elevate plasma triglycerides leading to pancreatitis; discontinuation may be necessary<\/li><li>hypothyroidism, estrogen increases thyroid-binding globulin levels, monitoring recommended<\/li><li>hypoparathyroidism, estrogen induced hypocalcemia may occur<\/li><li>ovarian cancer; increased risk with long term estrogen treatment (5 years or longer) with or without progestin<\/li><li>retinal vascular thrombosis has been reported; discontinue if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine; discontinue permanently if papilledema or retinal vascular lesions are observed<\/li><li>surgeries that are associated with increased risk of thromboembolism or periods of prolonged immobilization; increased risk of thromboembolism; drug discontinuation is recommended 4 to 6 weeks before procedure<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"923256-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"923256-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"923256-s-4","title":"Drug Interactions","sub":[{"id":"923256-s-4-13","title":"Contraindicated","mono":"<ul>Tranexamic Acid (probable)<\/ul>"},{"id":"923256-s-4-14","title":"Major","mono":"<ul><li>Bupropion (theoretical)<\/li><li>Carbamazepine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Isotretinoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Theophylline (theoretical)<\/li><\/ul>"},{"id":"923256-s-4-15","title":"Moderate","mono":"<ul><li>Alprazolam (probable)<\/li><li>Amprenavir (probable)<\/li><li>Aprepitant (probable)<\/li><li>Atazanavir (probable)<\/li><li>Bacampicillin (probable)<\/li><li>Betamethasone (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bosentan (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Colesevelam (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Delavirdine (probable)<\/li><li>Efavirenz (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Etravirine (probable)<\/li><li>Fosamprenavir (established)<\/li><li>Fosaprepitant (probable)<\/li><li>Fosphenytoin (probable)<\/li><li>Ginseng (probable)<\/li><li>Griseofulvin (established)<\/li><li>Itraconazole (probable)<\/li><li>Ketoconazole (probable)<\/li><li>Lamotrigine (established)<\/li><li>Levothyroxine (probable)<\/li><li>Licorice (probable)<\/li><li>Modafinil (probable)<\/li><li>Mycophenolate Mofetil (probable)<\/li><li>Mycophenolic Acid (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Oxcarbazepine (probable)<\/li><li>Phenobarbital (probable)<\/li><li>Phenytoin (probable)<\/li><li>Prednisolone (established)<\/li><li>Primidone (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Rufinamide (probable)<\/li><li>Selegiline (probable)<\/li><li>St John's Wort (established)<\/li><li>Telaprevir (established)<\/li><li>Tipranavir (established)<\/li><li>Topiramate (probable)<\/li><li>Troglitazone (probable)<\/li><li>Troleandomycin (established)<\/li><li>Voriconazole (established)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"923256-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (7% to 17%), Nausea (4% to 8%)<\/li><li><b>Neurologic:<\/b>Headache (14% to 19%)<\/li><li><b>Psychiatric:<\/b>Depression (4% to 8%)<\/li><li><b>Reproductive:<\/b>Dysmenorrhea (3% to 13%), Pain of breast (13% to 36%)<\/li><li><b>Respiratory:<\/b>Pharyngitis<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, Myocardial infarction<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder<\/li><li><b>Hematologic:<\/b>Venous thrombosis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Dementia<\/li><li><b>Ophthalmic:<\/b>Thrombosis of retinal vein<\/li><li><b>Reproductive:<\/b>Breast cancer, Endometrial carcinoma, Ovarian cancer<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"923256-s-6","title":"Drug Name Info","sub":{"0":{"id":"923256-s-6-17","title":"US Trade Names","mono":"<ul><li>Premphase<\/li><li>Prempro<\/li><li>Prempro Low Dose<\/li><\/ul>"},"2":{"id":"923256-s-6-19","title":"Class","mono":"<ul><li>Estrogen<\/li><li>Estrogen\/Progestin Combination<\/li><li>Progestin<\/li><\/ul>"},"3":{"id":"923256-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923256-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923256-s-7","title":"Mechanism Of Action","mono":"<ul><li>Estrogens bind to nuclear receptors in estrogen-responsive tissues. Binding modulates the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism thereby reducing the levels of these gonadotropins seen in postmenopausal women.<\/li><li>MedroxyPROGESTERone acetate does not have significant estrogenic activity; however, its beneficial effect on the endometrium appears to be by way of decreasing nuclear estrogen receptors and suppresses epithelial DNA synthesis in endometrial tissue.<\/li><\/ul>"},"8":{"id":"923256-s-8","title":"Pharmacokinetics","sub":[{"id":"923256-s-8-23","title":"Absorption","mono":"<ul><li>Total estrone, Tmax: 6.1 to 9.1 hours<\/li><li>Baseline adjusted total estrone, Tmax: 6.1 to 9.1 hours<\/li><li>Total equilin, Tmax: 4.6 to 7 hours<\/li><li>Conjugated Estrogens, Bioavailability: well-absorbed<\/li><li>Total estrone, Effect of food: Cmax 18% to 34% lower<\/li><li>Total Equilin, Effect of food: Cmax 38% greater<\/li><li>MedroxyPROGESTERone acetate, Tmax, Oral: 2.4 hours to 2.8 hours<\/li><li>MedroxyPROGESTERone Acetate, Bioavailability: well-absorbed<\/li><li>MedroxyPROGESTERone acetate, Effect of food: Cmax doubled; AUC 20% to 30% greater<\/li><\/ul>"},{"id":"923256-s-8-24","title":"Distribution","mono":"<ul><li>Estrogen, Protein binding: extensive, to sex hormone binding globulin and albumin<\/li><li>MedroxyPROGESTERone acetate, Plasma proteins: approximately 90%<\/li><li>Estrogen, Vd: widely distributed<\/li><\/ul>"},{"id":"923256-s-8-25","title":"Metabolism","mono":"<ul><li>Conjugated Estrogens, Liver: extensive via CYP3A4 and conjugation<\/li><li>Conjugated Estrogens: estradiol, estrone, and estriol (all active)<\/li><li>MedroxyPROGESTERone Acetate, Liver: extensive via hydroxylation and conjugation<\/li><\/ul>"},{"id":"923256-s-8-26","title":"Excretion","mono":"<ul><li>Conjugated Estrogens, Renal: extensive, primarily as metabolites<\/li><li>Conjugated Estrogens, Bile: minor pathway<\/li><li>MedroxyPROGESTERone acetate, Renal: extensive, primarily as metabolites<\/li><\/ul>"},{"id":"923256-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Conjugated Estrogens: 11.4 to 23.6 hours<\/li><li>MedroxyPROGESTERone acetate: 37.6 to 46.3 hours<\/li><\/ul>"}]},"10":{"id":"923256-s-10","title":"Monitoring","mono":"<ul><li>appropriate bone mineral density is indicative of efficacy<\/li><li>improvement in severity of vasomotor symptoms is indicative of efficacy<\/li><li>improvement of vulvar and vaginal atrophy and related symptoms is indicative of efficacy<\/li><li>thyroid function in patients who receive thyroid hormone replacement therapy<\/li><li>yearly breast examinations; mammography examinations based on patient's age, risk factors, and prior mammogram results<\/li><li>fluid status, especially in women with predispositions (eg, cardiac or renal impairment)<\/li><\/ul>"},"11":{"id":"923256-s-11","title":"How Supplied","mono":"<ul><li><b>Premphase<\/b><br\/>Oral Tablet: (Conjugated Estrogens - Medroxyprogesterone Acetate) 0.625 MG-5 MG<br\/><\/li><li><b>Prempro Low Dose<\/b><br\/>Oral Tablet: (Conjugated Estrogens - Medroxyprogesterone Acetate) 0.45 MG-1.5 MG<br\/><\/li><li><b>Prempro<\/b><br\/>Oral Tablet: (Conjugated Estrogens - Medroxyprogesterone Acetate) 0.3 MG-1.5 MG, 0.45 MG-1.5 MG, 0.625 MG-2.5 MG, 0.625 MG-5 MG<br\/><\/li><\/ul>"},"12":{"id":"923256-s-12","title":"Toxicology","sub":[{"id":"923256-s-12-31","title":"Clinical Effects","mono":"<ul><li><b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic.<br\/><\/li><li><b>PROGESTINS<\/b><br\/>OVERDOSE:  Rarely do acute ingestions result in obvious clinical manifestations.  CHRONIC: Most  adverse effects are related to chronic or high-dose therapy.  Headache, dizziness, irregular menses, mastalgia, bloating, depression, decreased libido, cholestatic jaundice, hepatitis, oligomenorrhea, amenorrhea and thromboembolism may occur with chronic therapy.<br\/><\/li><\/ul>"},{"id":"923256-s-12-32","title":"Treatment","mono":"<ul><li><b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul><\/li><li><b>PROGESTINS <\/b><br\/><ul><li>Support: Single acute overdoses will seldom result in toxicity.  Supportive treatment is adequate in most situations.<\/li><li>Decontamination: Gastric decontamination is probably only necessary after very large ingestions or with toxic coingestants; administer activated charcoal in these cases.<\/li><li>Monitoring of patient: CHRONIC TOXICITY: Discontinue medication and monitor for signs of toxicity and treat symptomatically.  Obtain a baseline CBC and hepatic and renal function tests in symptomatic patients.<\/li><\/ul><\/li><\/ul>"},{"id":"923256-s-12-33","title":"Range of Toxicity","mono":"<ul><li><b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations.<br\/><\/li><li><b>PROGESTINS<\/b><br\/>Toxicity is unlikely following an acute overdose.  There are insufficient data reported in the literature to assess the range of toxicity in terms of mg\/kg ingested.<br\/><\/li><\/ul>"}]},"13":{"id":"923256-s-13","title":"Clinical Teaching","mono":"<ul><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, deep vein thrombosis, thrombophlebitis, dementia, pulmonary embolism, or breast cancer.<\/li><li>Instruct patient to immediately report signs\/symptoms of serious cardiovascular events such as myocardial infarction, stroke, venous thrombosis, or pulmonary embolism.<\/li><li>This drug may cause abdominal pain, nausea, vomiting, back pain, headache, depression, breast pain and tenderness, pharyngitis, sinusitis or gallbladder disease.<\/li><li>Advise patient to report sudden onset migraine, diplopia, or partial or complete loss of vision, as drug may cause retinal vascular thrombosis.<\/li><li>Advise patient to immediately report abnormal vaginal bleeding.<\/li><li>Patient should not smoke during therapy, as this increases the risk of serious cardiovascular side effects.<\/li><li>Patient should avoid eating grapefruit or drinking grapefruit juice while taking this drug.<\/li><\/ul>"}}}